Full Report

Pernod Ricard: a spirits leader marked down 70%

Pernod Ricard, the world's second-largest spirits group — Absolut, Jameson, Martell, Chivas Regal, Havana Club, Ricard — trades at €63.88, roughly 70% below its April 2023 all-time high near €218 [1]. It was one of the CAC 40's worst performers in 2025 while the index rose. The fall is deep and forced enough to fit the setup Ruchir hunts. The report's spine is whether it prices a temporary external shock — China's cognac tariffs, US destocking, currency — or a structural decline in spirits demand. It clears the size floor; leverage and a sub-10% cash yield temper the fit.

What Pernod Ricard is

Created by the 1975 merger of Pernod and Ricard, the group sells premium spirits, plus Champagne, ready-to-drink and rosé wine, through a portfolio of 200-plus brands in more than 160 countries; spirits are about 90% of net sales [2]. FY2025 (year ended 30 June 2025) consolidated net sales were €10,959 million [3]. The business is a "grain-to-glass" model: owned distilleries and long-aged inventories (cognac, whisky, tequila) feed a global distribution network, and value is created by brand pricing power and premiumisation rather than volume growth.

Revenue peaked in FY2023 and has fallen for two years since; group net profit and earnings per share fell with it.

Source: FY2025 Universal Registration Document, key figures from the consolidated financial statements [4]; prior years as reported.

Reported diluted EPS moved from €8.81 in FY2023 to €5.83 in FY2024 and €6.45 in FY2025 [5]. Sales are weighted toward Asia and the rest of the world, which makes the group's largest region also its most disrupted.

Source: FY25 Full-Year Sales and Results press release, net sales by region [6].

The dislocation

The trajectory is a slow-motion collapse rather than a single-day crash. From an April 2023 all-time high near €218, the shares lost about a quarter of their value by autumn 2023, kept falling through 2024 and 2025 — a decline of roughly a third in calendar 2025 alone, against a CAC 40 that gained about 10% — and reached the low €70s by the start of 2026. A relief rally to €86.84 in February 2026 gave way to a fresh low of €59.94 in March; the shares closed at €63.88 on 3 July 2026.

Source: 2023–early 2026 levels as reported by financial media; February–July 2026 levels from the daily price feed, as reported.

Source: price and share count as reported (252.0 million shares); dividend of €4.70 per share from the FY25 results release [7].

The trigger is not a fraud or a broken balance sheet but a stack of external shocks landing on the two most profitable ends of the portfolio. FY2025 organic net sales fell 3.0% (5.5% reported), with a €277 million currency drag from the Turkish lira, Argentine peso and Indian rupee [8]. China sales fell 21% and the United States fell 6%, while India grew 6% [9]. China's decline compounds a specific policy shock: an anti-dumping investigation prompted the suspension of duty-free cognac imports from December 2024 and provisional duties reported at about 30.6% on Martell, the group's flagship cognac, so its most premium brand was hit by both weak demand and a tariff. Management frames FY2026 as a transition year, with a first-quarter decline on US distributor destocking, continued Chinese inventory adjustment, Indian excise changes in Maharashtra, and duty-free cognac in China resuming only from the second quarter [10].

Alongside those cyclical and policy shocks sits a slower fear that is harder to dismiss: moderation. Western consumers, and Gen Z in particular, are drinking less, and GLP-1 weight-loss drugs are associated with lower alcohol intake in early studies. The company's own filing argues the opposite for its segment — that international spirits are still taking value share from beer and wine, that premium-and-above spirits have grown mid-single digits a year for a decade, and that spirits penetration among Gen Z is rising [11]. Which read is right is the pivot of the whole case, and later chapters test it against the data.

What the price implies

At €63.88 the equity is worth about €16.1 billion. Net financial debt was €10,727 million at 30 June 2025, so enterprise value is roughly €27 billion [12]. Against trailing reported earnings that is under ten times profit and about eight times EBITDA — undemanding for a premium-spirits franchise, though the number depends on where earnings settle: consensus has FY2026 EPS near €5.77, another step down, which lifts the forward multiple.

Source: derived from reported financials — market cap at €63.88; net debt and free cash flow from the FY2025 net-debt statement [13]; net debt / EBITDA of 3.3x per the results release [14].

Two of Ruchir's reference lines land on the soft side. Reported free cash flow of €1,133 million against the market value is a 7.0% yield; on the group's recurring free-cash-flow measure of €1,348 million it is about 8.4% [15]. Both sit below his roughly-10% marker, though a further price fall or an earnings recovery would close the gap. And this is not the debt-light balance sheet he prizes: net debt of about €11 billion is 3.3x EBITDA, a leverage multiple up on the year largely on currency [16]. The dividend deserves an early flag: at €4.70 per share the cash cost was €1,201 million in FY2025, more than the €1,133 million of reported free cash flow that year and covered only on the recurring measure [17]. The 7%-plus yield is real; whether it is safe is a question for its own chapter.

The universe and exclusion screen

Source: listing status as reported (Pernod Ricard deregistered from the SEC in 2007 and trades in the US over-the-counter); market cap derived from the €63.88 price; regional and demand facts per the FY2025 filings cited above.

The screen is mostly clean, with two things to state plainly on the first page. First, this is a European large-cap, not a US-listed stock: American investors reach it through an over-the-counter Level I ADR, not an exchange listing, which narrows the instruments available and puts it at the edge of Ruchir's stated universe. Second, China is a real dependency — the group's largest region carried its steepest decline — and the moderation debate is unresolved. Neither is a disqualifier by itself; both are exactly the facts he would rather hear on page one than page ten. On the family-controlled management, the founding Ricard family's continued control is prima facie alignment rather than the promotional, next-quarter-EPS pattern he excludes, but that is for the governance chapter to test against the record.

The question this report answers

The setup is genuine. A high-quality, cash-generative global brand owner has fallen about 70% on a run of external shocks, with holders who bought it as a defensive compounder now selling a name that no longer behaves like one. That is the kind of forced, price-anchored selling that can leave intrinsic value largely intact. The report exists to test that directly: whether the value of the business has fallen anywhere near as far as the price, or whether the shocks — above all the demand question — mark a permanent step down in earning power. The balance sheet's leverage and a cash yield still short of Ruchir's line are the features that keep this from being a textbook fit, and they run through everything that follows.

---

Damage Arithmetic

Pernod Ricard's operating earnings have barely moved off their peak, yet the equity has lost roughly seven-tenths of its value. Profit from recurring operations fell about 12% from the FY2023 high and EBITDA about 10%, while enterprise value fell about 57% and the market capitalisation about 70%. Almost the entire enterprise-value decline is multiple compression, not lost earnings — and financial leverage turns that into a still larger equity move. The gap between price damage and business damage is wide; whether it is an opportunity depends entirely on whether the earnings shortfall is temporary.

The earnings hit against the price hit

The starting point is to put the two declines side by side on the same clock — from the FY2023 peak to today — measured in the company's own reported figures.

At the operating line, the damage is modest. Profit from recurring operations (PRO), the group's headline profit measure, peaked at €3,348m in FY2023 and was €2,951m in FY2025 [1][2] — a decline of 11.9%. Operating margin held at 26.9% of net sales [3]. The damage grows as you move down the income statement: statutory group net profit fell from €2,262m in FY2023 to €1,626m in FY2025, down 28% [4], as higher interest expense, a higher tax charge, and a FY2024 impairment absorbed more of a smaller operating base. On the recurring earnings-per-share line that consensus follows, the fall is larger still: €9.11 in FY2023, €7.90 in FY2024, €7.26 in FY2025 [5][6], and consensus for FY2026 sits near €5.77 — about 37% below the peak.

Against that, the price. The shares peaked at €218.00 during FY2023 and last traded at €63.88, a drawdown of roughly 71% (Dislocation and Screen sets the trigger stack behind it). Market capitalisation at the June-2023 year-end was €51,740m; at €126.70 a year later it was €32,097m; today it is about €16.1bn [7][8].

Source: PRO, EBITDA and net profit from FY2023 and FY2025 URDs [9][10]; EPS and market values from stock-market-data tables [11][12]; FY2026 EPS is consensus, as reported.

The spread across these bars is the whole point. Take the operating measure and the price move together, and the equity fell roughly six times as far as PRO. Take the harshest earnings measure — recurring EPS out to the FY2026 consensus trough — and the equity fell about twice as far. The truth sits between: the operating engine is lightly dented, but leverage, tax, and FX magnify a small top-line problem into a real net-profit decline, and the share price then moves several times that.

Where the enterprise value went

Because the equity is what is left after the debt, the cleaner way to see the damage is at the enterprise-value level, then decompose it into the two things that can move it — how much the business earns, and the multiple the market pays for those earnings.

Source: equity from stock-market-data (market cap) [13]; net debt of €10,273m (FY23) [14] and €10,727m (FY25) from the net-debt reconciliation [15]; EBITDA is PRO plus depreciation; current equity derived from €63.88 on ~252m shares.

Enterprise value fell from about €62.0bn to about €26.8bn — a 57% decline. EBITDA over the same window fell about 10%. The rest is the multiple: EV/EBITDA compressed from roughly 16.5x to about 8.0x. Decomposed, the 57% enterprise-value decline is roughly one-eighth lost earnings and seven-eighths a lower multiple. The market has not written down what Pernod earns; it has re-rated the business from a premium-staples multiple to one it assigns to a shrinking franchise.

Leverage then does the last step. Net debt sat near €10.3–10.7bn at both points and barely moved [16]. With the debt fixed, the entire €35bn of enterprise-value loss fell on the equity — which is why a 57% EV decline became a 70% equity decline. At 3.3x net debt to EBITDA [17], that amplification is a permanent feature of the equity, not a temporary one: it will also amplify any EV recovery on the way back up.

Source: derived from reported PRO, EBITDA, net debt and market values, FY2023–FY2025 URDs [18][19].

What the current price implies

A second lens asks what growth the current price already bakes in. Treat the equity as a perpetuity of free cash flow: at €63.88 the market values the equity at about €16.1bn, against FY2025 free cash flow of €1,133m as reported and €1,348m on the group's recurring measure [20]. Solving a simple Gordon-growth relationship for the perpetual growth rate the price implies, across a range of discount rates, gives the following.

Source: derived from €16.1bn market cap and FY2025 free cash flow of €1,133m / €1,348m [21]; Gordon-growth solution, assumptions stated.

The answer clusters near zero: at an 8–9% cost of equity, the price implies perpetual free-cash-flow growth of roughly minus 0.3% to plus 1.8%, depending on which cash-flow figure is used. For a business whose profit from recurring operations compounded from €2,581m in FY2019 to €3,348m in FY2023 — about 6.7% a year [22] — the price is set for something close to a permanent stall. That is a statement about the future, not the past: the reverse-DCF does not say the market is wrong, only that it has stopped paying for growth.

Source: FY2019–FY2023 from the FY2023 URD indicators [23]; FY2024–FY2025 from the FY2025 URD income statement [24].

Bounding the intrinsic damage

The final step is to price the disclosed problem directly. Suppose the shock is exactly what management describes — a stretch of depressed earnings that eventually recovers to the prior run-rate. How much present value does that actually destroy?

Take the operating shortfall against the FY2023 peak: PRO ran €232m below peak in FY2024 and €397m below in FY2025. Extend that a conservative path — a wider €500m gap in FY2026, then €350m and €150m in FY2027–FY2028, before full recovery to the peak run-rate. The cumulative shortfall is about €1.6bn of pre-tax PRO, roughly €1.2bn after tax, and about €1.0–1.1bn in present value at an 8% discount. Double both the depth and the duration — a €500m annual net shortfall sustained for six years — and the present value is still under €3bn.

Source: derived from the PRO shortfall against the FY2023 peak [25][26]; discounted at 8%, assumptions stated; enterprise value removed from the EV decomposition above.

The comparison is stark. A temporary problem, taken to a pessimistic-but-honest extreme, explains on the order of €1–3bn of present value. The market removed about €35bn of enterprise value and roughly €36–40bn of equity value. For the price to be right, the loss cannot be a passing shortfall in earnings; the multiple re-rating has to be permanent — the business must be worth 8x EBITDA rather than 16x forever, which is the same as saying the recurring cash flows never grow again. That is the assumption the whole gap rests on, and it is the temporary-versus-permanent demand question the rest of the report has to settle.

What narrows the gap

Three facts cut against reading the whole gap as free money.

First, the net-line damage is not the small hit the classic dislocation frame assumes. Recurring EPS is down about 37% from the peak to the FY2026 consensus trough, and estimates are still being cut — the FY2026 consensus of about €5.77 is roughly 21% below FY2025 [27]. The operating trough may not yet be in the reported numbers, and if the demand problem proves structural, today's earnings still overstate the eventual run-rate.

Second, the cash return sits below the level that would make the gap self-evidently cheap. FY2025 free cash flow was €1,133m reported and €1,348m recurring, against a €16.1bn market cap — a free-cash-flow yield of 7.0% to 8.4% [28], short of the roughly 10% mark this reader's framework treats as the reference line. The 3.3x leverage that amplifies the equity on the way up also raises the stakes if the recovery is slow.

Third, and on the other side, the most recent trading points toward stabilisation rather than deterioration. In the third quarter of FY2026 organic net sales were roughly flat at +0.1%, total group volumes returned to growth at +4%, and outside the still-contracting US and China markets the rest of the world grew about +5%; the steep 14.8% reported decline over nine months is mostly currency (a €515m foreign-exchange drag) and the disposal of the Wines and Imperial Blue businesses (€393m), not organic collapse [29]. That reported-versus-organic split matters: it means the headline top-line damage overstates the deterioration in the underlying business, which is consistent with an operating engine that is bruised rather than broken.

The arithmetic, then, is two-sided but clear on where it points. The price has fallen far more than the business has, and most of that is a lower multiple that would reverse if growth returns. What it cannot tell you is whether growth returns — and that read would change if the demand data showed Western spirits consumption declining structurally rather than cyclically, in which case a permanently lower multiple is the correct answer rather than the market's error.

---

Demand Durability

The case is most sensitive to one input: whether the premium-spirits demand Pernod monetises is temporarily depressed or structurally lower. The balance of evidence points to a cyclical, affordability-driven downturn with a real structural overlay. Volumes are recovering across the industry, but the premiumisation pricing that drove the FY2022–23 boom has inverted into downtrading — at Pernod and at every peer. Demand is not disappearing; the pricing power behind the old multiple has not yet returned.

The growth the market paid for

Pernod's investment case was built on a specific claim about its market: that international premium-plus spirits — its core segment — compounded at roughly +7% a year over the decade to 2023, against +6% for total spirits and +4% for all beverage alcohol [1]. On the strength of that, management set a medium-term framework of "the upper end of +4% to +7%" organic net-sales growth [2]. A 16x EV/EBITDA multiple is a coherent price for a business growing mid-single-digits with expanding margins.

In April 2026 that framework was reset. The new through-cycle algorithm is +3% to +6% organic growth for FY2027–29 [3]. Management lowered the ceiling and the floor of its own long-run growth rate by a point. That is a small revision in isolation, but it is the company itself conceding that the mid-cycle base is lower than the one the 16x multiple was paying for.

The premiumisation engine reversed

The clearest read on temporary-versus-permanent is in how Pernod's organic growth splits between volume and price/mix. Price/mix — pricing plus the shift toward more expensive bottles — is premiumisation made visible. Volume is the count of cases sold.

Source: Pernod Ricard FY2022 [4], FY2023 [5], FY2024 [6], FY2025 [7] and H1 FY2026 [8] sales releases (Strategic International Brands).

Two distinct phases sit inside that chart. FY2022–23 was the post-pandemic boom: volumes surged +16 points in FY2022, then in FY2023 volume went flat while price/mix carried +11 points, the cyclical peak of the pricing-and-mix push [9]. FY2024 was a volume problem with premiumisation intact: volumes fell −5 points on US and China destocking, but price/mix stayed positive at +2 points [10]. Had the story ended there, "temporary" would be the easy read: destock, then re-stock.

The inflection is FY2025. Volumes recovered to flat, but price/mix turned negative for the first time in the series, at −5 points [11]; the group's overall organic net sales fell −3.0% to €10,959m [12]. Price/mix stayed negative into H1 FY2026 at −4 points, alongside a −3 volume [13]. Premiumisation did not slow; it went into reverse. The engine that carried +11 points in FY2023 is now subtracting.

Source: Pernod Ricard FY2023 [14], FY2025 [15] and Q3 FY2026 [16] sales releases.

It is the category, not the company

If this were a Pernod execution failure, its peers would be pulling ahead. They are not. The same shape — volumes holding or growing, price/mix rolling over — runs through every major premium-spirits house on its most recent results.

Sources: Pernod Ricard FY2025 release [17]; Diageo FY2025 Annual Report [18]; Brown-Forman FY2026 Annual Report [19]; Rémy Cointreau 9M FY2026 sales call [20].

Diageo, the industry's largest player, grew organic net sales +1.7% in the year to June 2025, on +0.9% volume and +0.8% price/mix — but it too flagged "consumer downtrading in South East Asia and China," and noted that "when the consumer wallet is under pressure, scotch is typically one of the most adversely impacted categories" [21] [22]. Brown-Forman ran flat organically in its year to April 2026, with volume +5% fully offset by price/mix −5% — the textbook downtrading signature [23]. Rémy Cointreau is the starkest: 9M FY2026 organic −1.9%, made of +4.5% volume against −6.4% price/mix; its cognac division sold +5.4% more volume yet took −9.7% on price/mix [24] [25].

Independent US category data carry the same reading. Per the Distilled Spirits Council's 2025 figures, US supplier sales fell 2.2% in value while volumes rose 1.9%; super-premium-and-above spirits dropped about 15% in value, and the one growth category was spirits-based ready-to-drink cocktails, up 16.4%. Consumers kept buying spirits — they traded down and shifted format. That pattern is consistent with an affordability cycle, not a walk-away from the category.

The structural overlay Pernod concedes

The downtrading is cyclical in character, but demand is not moving on price alone. In its February 2026 deck, Pernod made the affirmative case that the erosion is not structural: US beverage-alcohol servings per month were roughly stable from 2018 to 2025, bottled spirits were gaining share of total servings (from 21% to 30% of servings), household penetration of spirits held near 67%, and it presented Gen-Z consumption as rising as the cohort ages into legal purchasing — while judging GLP-1 weight-loss drugs to cause "limited disruption to spirits" [26].

That deck is the bull case, and parts of it warrant scrutiny. "Stable servings" is itself an admission that category volume is not growing — the entire +4% to +7% ambition assumed a growing base. The Gen-Z series it shows is five quarters long and volatile (33%, then a spike to 55%, back to 45%), thin evidence for a durable trend. The honest counterweight is management's own May 2026 US webcast, which is more candid than the deck. Pernod's North America CEO put US bottled spirits ex-RTD "at around minus 5% in value" year-to-date, called the pressures "primarily cyclical, but not exclusively so," and named the non-cyclical drivers directly: "health and wellness, moderation, GLP-1, and generational shifts are also having an impact on spirits consumption" [27].

That is the fair synthesis. The dominant driver of today's softness is affordability and destock — cyclical, and reversible as wallets normalise. But a structural layer is real and acknowledged by the company: moderation, GLP-1, and a generation drinking less. It is second-order today, and it works on volume more than it explains the price/mix collapse. The reason it matters is duration — a cyclical trough reprices when the cycle turns; a structural drift compounds slowly against the multiple for years.

The tentative turn

The most recent data point cuts toward cyclical. In Q3 FY2026, group organic net sales returned to +0.1%, with total volumes back to +4% growth; stripping out the US and China — the two markets still contracting, at −12% and −7% in the quarter — the rest of the world grew +5%, and cognac shipments to China resumed after the duty-free suspension lifted [28]. Volume is doing what volume does after a destock: it comes back. The unresolved half is price/mix, which was still negative through H1 and which the recovery in volumes has not yet reversed.

The distinction that decides the chapter is therefore narrower than "temporary or permanent" in the abstract. On volume, the evidence for temporary is strong: penetration is stable, peers are all seeing units recover, and Pernod's own Q3 volumes turned. On price/mix — the premiumisation that justified the old multiple — the evidence is genuinely open. If downtrading is an affordability response that unwinds as real incomes recover, price/mix returns to positive and the 16x-era earning power is intact. If consumers have permanently reset to cheaper bottles and smaller formats, mid-cycle earning power is structurally lower, and the roughly 8x multiple the market now assigns is closer to right than wrong.

What would move the read, in order of information value: group price/mix returning to positive at the next full-year result; the US value trend crossing back above zero; and whether the +3% to +6% algorithm holds or is cut again. Those are the falsifiable markers. Until price/mix turns, the reduced earning power management has already written into its own framework is the fact on the page, and the burden sits with the recovery, not the decline.

---

Cash and the Dividend

The fall lifted Pernod Ricard's cash and dividend yields, but not to the lines this framework uses. Reported free cash flow yields about 7.0% (8.4% on the group's recurring measure) and the dividend yields about 7.4% — both short of the ~10% reference. The €4.70 dividend, frozen since FY2023, is no longer covered by reported free cash flow and now absorbs about 65% of recurring profit against a ~50% policy. Leverage sits at 3.3x with no financial covenant, ample liquidity — and buybacks that stopped at the lows.

The yield rose, but not to the line

At €63.88, Pernod Ricard's roughly 252 million diluted shares carry a market value near €16.1bn [1]. Against that, FY2025 free cash flow of €1,133m as the company reports it — €1,348m on its recurring measure — puts the free-cash-flow yield at 7.0% to 8.4%, and the €4.70 dividend yields 7.4% [2].

Sources: market value derived from the FY2025 reported share count and the €63.88 price [3]; FCF and dividend from the FY2025 net-debt reconciliation [4]; net debt/EBITDA of 3.3x per company disclosure [5].

This is the first place the setup looks different from a textbook dislocation. In the classic version the price fall alone drives the free-cash-flow yield past 10%, because cash generation holds while the denominator collapses. Here the yield stalls in the 7% to 8% range because the numerator fell too: FY2025 reported free cash flow of €1,133m is down from €1,813m in FY2022 [6]. A cheaper price met a smaller cash flow, so the yield sits below the reference line rather than through it.

Why the cash flow is depressed

Pernod Ricard converts profit to cash more slowly than most consumer-staples peers because it must pre-fund years of maturing spirit — inventory stands at €8.4bn, and the group invests continuously in strategic inventories and distillation capacity. Both of those calls are discretionary in timing, and both were run hot through the boom.

Source: operating cash flow, capital expenditure and free cash flow derived from reported financials, FY2022–FY2025 [7].

Free cash flow troughed at about €1.0bn in FY2024, which management attributed directly to "an increase in planned investments in capex and maturing inventories" landing at the same time profit fell [8]. Capital expenditure rose from 4.7% of sales in FY2022 to 6.7% in FY2024 before easing to 6.1% in FY2025, and free cash flow recovered 18% to €1,133m as that spend began to normalize [9].

The direction from here is the more important point. Management has guided strategic investments below €900m in FY2026 and to no more than about €1bn medium-term, with cash conversion targeted at circa 80% and above and a €1bn efficiency programme through FY2029 [10]. Run those targets forward: if recurring net profit recovers toward the €2.0bn it posted in FY2024 and conversion reaches 80%, recurring free cash flow lands near €1.6bn — about a 10% yield on today's market value [11].

Source: reported and recurring FCF yields on FY2025 cash flow [12]; the normalized bar is illustrative — recurring net profit recovering to ~€2.0bn at ~80% cash conversion, derived from management's medium-term targets [13].

So the ~10% line is reachable, but only on a double recovery: the earnings base has to climb back toward FY2024 and cash conversion has to improve at the same time. Neither is delivered. The reading that fits the evidence is that this cash engine is pointed the right way — normalizing capex and inventory release cash even at flat profit — while sitting one recovery short of the yield the framework looks for. What would move it up is a return of recurring net profit toward €2bn with strategic investment held under €1bn; what would keep it stuck is a second year of falling profit that offsets the investment normalization.

The dividend: frozen, and now above policy

Pernod Ricard's stated policy is a payout of "circa. 50% of net profit from recurring operations, with the aim of increasing the dividend each year" [14]. It honored that policy on the way up — the dividend grew from €3.12 in FY2021 to €4.70 in FY2023, each year near a 50% payout. Then it froze. The board has held €4.70 for three consecutive years while recurring net profit per share fell from €9.11 to €7.26, so the payout ratio has climbed to about 65% [15].

Source: dividend per share and five-year dividend record [16]; recurring net profit per share FY2021–FY2023 [17] and FY2024–FY2025 [18].

Two facts sit in tension. On the coverage side, the dividend is not covered by reported cash: €1,201m paid against €1,133m of reported free cash flow is 0.94x, and FY2024 was worse at 0.80x — it clears only on the recurring measure, at 1.12x [19]. And measured against the company's own policy, the current €4.70 is about 30% above where a strict 50% payout on FY2025 recurring profit per share (€7.26) would put it — roughly €3.63 [20].

Against that, the dividend has genuine support. Reported free cash flow grew 18% in FY2025 even as profit fell, narrowing the coverage gap [21]. Liquidity is not the constraint (below). And management has repeatedly framed the flat payout as deliberate and policy-aligned rather than stretched — at the FY2024 results it proposed the dividend "flat versus last year of €4.70 per share, fully aligned with our financial policy" [22].

The honest read is that this is a covered-but-not-comfortable dividend, not the high-conviction, hard-to-cut payout a yield-led case needs. It is defensible today; it is not underwritten with high conviction. The condition that would force a cut is specific: a second leg down in recurring profit that pushes the payout well beyond policy, or pressure on the investment-grade rating that makes deleveraging the priority. Cutting €4.70 back to the ~€3.63 the policy implies would free roughly €270m a year — the single largest discretionary lever the group has left, now that buybacks are already near zero.

Leverage and the balance sheet

Net debt closed FY2025 at €10.7bn, or 3.3x EBITDA — up from 3.1x a year earlier [23]. That increase runs against management's FY2024 guidance that "our leverage ratio is to improve as reported profit from recurring operation growth normalizes" [24]. Profit did not normalize, so leverage drifted the wrong way.

The cost of that debt is rising as low-coupon bonds mature into a higher-rate market. Pernod Ricard's bond stack still carries coupons as low as 0.125% to 1.75% from 2019–2022 issuance, while new paper prices at 3.25% to 3.75% — the €800m issued in March 2025 pays 3.25% [25]. Reported financial expenses rose to €584m in FY2025 from €505m a year earlier [26], and management put the average cost of debt at 3.2% and climbing [27]. As the sub-1% bonds issued in the zero-rate years refinance at today's coupons, that charge keeps building — a structural drag on pre-tax profit, independent of the demand cycle.

What the balance sheet does provide is time. The group's bank and bond contracts carry no financial-leverage covenant — the credit agreements "do not include any covenants stipulating compliance with financial leverage ratio (e.g., net debt/EBITDA)" [28]. Liquidity is deep: €1.8bn of cash, an undrawn €2.1bn sustainability-linked revolving facility extended to April 2030, and a laddered maturity profile with no wall — the nearest maturities are a €600m bond due May 2026 and a $600m bond due June 2026, comfortably inside cash and the facility [29]. The group can outlast a multi-year downturn on liquidity. The binding constraint is not a covenant or a maturity — it is the investment-grade rating management lists as its first priority, which is what makes rising leverage, not a refinancing cliff, the thing to watch.

Self-help ran backwards

Ruchir's self-help test asks whether management is buying alongside a contrarian at the lows. Here the record runs the other way. Pernod Ricard repurchased and cancelled €752m of stock in FY2022 at an average price near €190, and its financial policy places buybacks last — "carrying out share buybacks when all three priorities above are fulfilled" [30]. At the FY2023 results the group guided a further "share buyback program of €500m to €800m in FY24" [31]. It then executed only €334m in FY2024 — below its own plan — and just €11m in FY2025, effectively stopping [32].

Source: number of listed shares at 30 June, FY2021–FY2023 [33] and FY2022–FY2025 [34].

The share count fell from about 262 million in FY2021 to 252 million in FY2025 — a roughly 4% reduction — but almost all of it was bought at prices between €126 and €218, at an average well above €160 [35]. The repurchases wound down exactly as the price collapsed toward €64, and the count is now essentially flat. For a contrarian, the mechanical consequence matters more than the optics: with buybacks stopped, there is no share-count tailwind quietly lifting per-share earnings above consensus, and management is not signalling, with its own cash, that it sees the market's error. That is the reverse of the self-help pattern the framework rewards.

The cash chapter therefore cuts against the friendlier reading of the price-versus-intrinsic gap the report turns on: the yields are real but below the reference lines, the dividend is covered only on the recurring measure and sits above policy, and the one form of self-help that would compound a contrarian's edge has been switched off at the bottom. None of that makes the dislocation undeserved — that verdict rests on demand, settled elsewhere — but it removes the free options a cleaner balance sheet and an aggressive buyer would have added.

---

Cognac and China

One region carries the disproportion in this fall. Asia and the Rest of the World is 42% of Pernod Ricard's sales but 46% of its recurring profit, and it absorbed the deepest cut in FY2025 — driven by a −21% collapse in China and a −20% drop at Martell, its cognac house. Most of that shock is a Chinese demand cycle plus a trade dispute that is now resolved on a five-year footing; the cognac franchise beneath it is one of the most structurally protected assets in spirits. Whether Chinese cognac demand itself resets lower is the piece that is not yet settled.

Where the fall concentrated

Pernod reports profit by region, not by brand, and the regional split locates the damage precisely. In FY2025 the Asia/Rest-of-the-World region generated €4,635m of net sales — 42% of the group — but €1,360m of profit from recurring operations, 46% of the group's €2,951m [1]. Its 29.3% margin is the highest of the three regions, above the Americas (26.9%) and Europe (23.5%). This is where cognac, Chinese demand and Global Travel Retail concentrate, and it is the region that fell hardest.

Source: FY2025 Universal Registration Document, net sales and recurring profit by region [2].

The group does not break out Martell's revenue or profit, so its exact weight is an estimate rather than a disclosure. What can be anchored: Martell sold 1.9 million nine-litre cases in FY2025, and it is one of the four houses — with Hennessy, Rémy Martin and Courvoisier — that together hold roughly 87% of the value of the global cognac market [3]. On volume and typical cognac pricing, Martell is on the order of a tenth of group sales; because cognac carries above-group margins and sits inside the group's most profitable region and channel, its profit weight is higher than its sales weight. The precise figure is undisclosed, but the direction is not in doubt: cognac is a small slice of cases and an outsized slice of profit, and it led the group into the downturn.

The Martell decline came in two stages. In FY2023 the brand still grew net sales +10%, entirely on price/mix (+12 points) as volumes already softened (−3) [4]. FY2024 was a volume event — cases down 11% with pricing still positive (+1) [5]. FY2025 is when both broke at once: net sales −20%, volume −12 and price/mix −8 [6]. That volume-first, then-pricing sequence is the same pattern the Demand Durability chapter found across the group — but sharper at Martell, and with the added twist that its negative price/mix reflects the loss of a specific high-price channel, not only softer demand.

Source: FY2023, FY2024 and FY2025 Sales and Results press releases, Strategic International Brands tables [7]; [8]; [9].

Anatomy of the cognac shock

Two distinct forces hit Martell in FY2025, and they are worth separating because they resolve on different clocks.

The first is Chinese demand. China's organic net sales fell −21% in FY2025 against a "challenging macro-economic environment and continuing weak consumer sentiment" [10], following −10% in FY2024 [11]. Cognac is heavily exposed to the Chinese consumer — gifting, banqueting and the premium on-trade — so a Chinese slowdown lands on Martell harder than on the group.

The second is a trade action. In late 2024 China's authorities opened an anti-dumping probe into cognac (brandy) exports from the European Union [12], and cognac imports into China Duty Free were suspended from December 2024. Global Travel Retail — the airport and border channel where cognac sells at its highest prices — fell −13% for the year, with the company tying the outlook explicitly to "the resolution of the Cognac suspension in China Duty Free" [13]. Losing the duty-free channel is part of why Martell's price/mix turned negative: it is not that Martell cut list prices, but that its richest-mix outlet went dark.

Source: FY2024 and FY2025 Sales and Results press releases and Q3 FY2026 sales release [14]; [15]; [16]. Q3 FY26 is the quarter alone; nine-month China was −24%.

One point of management discipline shows up in the numbers and is worth flagging because it flatters the region's profit. Asia/RoW advertising and promotion spend was cut 12.7% organically in FY2025, well ahead of the −3.9% sales decline, which is why the region's recurring profit held to −1.2% organic even as its top line fell [17]. Protecting near-term profit by pulling brand investment is a lever, not a solution; it cannot be repeated indefinitely without eventually costing share.

A trade dispute, now resolved

The binary tail risk in this story — an open-ended tariff on cognac into China — has closed. On 5 July 2025 China's Ministry of Commerce issued its final ruling: definitive anti-dumping duties on EU brandy, effective five years, with dumping margins set between 27.7% and 34.9% (Martell 27.7%, Hennessy 34.9%, Rémy Martin 34.3%) — but the major houses, including Martell, avoided the duties by signing minimum-price undertakings, agreeing to sell at or above a set floor. Thirty-four EU producers were exempted from the duty on that basis (China Ministry of Commerce final ruling, 5 July 2025, as reported by Reuters, Bloomberg and Euronews).

The corpus confirms the mechanism and sizes its cost through the pure-cognac peer. Rémy Cointreau's management describes its guidance as including "the estimated impact from tariffs in the US and price undertakings in China," and puts the total China tariff effect at roughly €5m — a margin drag, not a demand wall [18]. For a house of Martell's scale the order of magnitude is comparable: the price undertaking trims margin at the edge, but it removes the risk of a punitive duty and lets the channel reopen.

And the channel has reopened. In Q3 FY2026 Pernod reported a "sales rebound following the resumption of Cognac sales in China DF," with Martell posting strong double-digit sell-out growth over Chinese New Year, while group volumes returned to +4% [19]. China's reported organic sales were still −7% in the quarter (−24% over nine months), so the underlying market has not recovered — but the specific, self-correcting piece of the shock, the duty-free suspension, is behind the company.

The moat under the shock

The reason the cognac question matters beyond one bad year is that cognac is among the most structurally defended categories in all of spirits, and Ruchir's framework asks whether the business will still be earning at scale in eight to twenty years. On cognac the answer is unusually clear, and it rests on three barriers that a well-funded competitor cannot simply buy.

The first is legal origin. Cognac is an appellation d'origine contrôlée: it can only be made from grapes grown in a defined region of south-west France, from a handful of designated crus [20]. No amount of capital creates new Cognac terroir. Pernod names this itself as an entry constraint on the category: "geographical origin and the need for long-term strategic inventories" [21].

The second is time locked in a barrel. Cognac is a blend of aged eaux-de-vie, and the finest can mature for decades — Rémy Cointreau notes an ageing potential of "more than 100 years for some Grande Champagne eaux-de-vie" [22]. That barrier shows up on Pernod's own balance sheet. Ageing inventories, held mainly for whisky and cognac, are 84% of total inventories [23], against total inventory of about €8.4bn — roughly a quarter of the group's entire asset base tied up in liquid maturing for years. On top of that the group holds €2,650m of forward supply commitments for eaux-de-vie, grapes and base wines [24]. A new entrant would need to start laying down stock today to compete a decade from now.

Source: FY2025 Universal Registration Document — 84% ageing share and €2,650m supply commitments [25]; [26]; total inventory as reported.

The third is concentration. Four houses hold about 83% of global cognac volume and 87% of its value [27]; Martell is one of them. The pure-cognac peer, Rémy Cointreau, runs the same model — cognac is 62% of its sales and over 99% of its international sales, sourced through decades-old exclusive grower partnerships covering the majority of the best crus [28]. This is an oligopoly protected by law, by time and by land. On the eight-to-twenty-year test, the cognac franchise reads as a wide, durable moat — the category will still exist and still be dominated by these houses. That is a genuinely different conclusion from the group-wide pricing question the Demand Durability chapter left open on the broader portfolio.

What could still be permanent

The moat being intact does not make the demand temporary, and the honest bear case sits precisely there. A protected franchise can still see its end-market reset to a structurally lower level, and China is where that risk lives.

Two facts keep the question open. First, Martell is more China-dependent than its diversified stablemates, so its recovery is hostage to the Chinese consumer specifically — and Chinese demand is entangled with a property-driven wealth shock and a shift in gifting and banqueting culture that may not fully reverse. Second, the pure-cognac peer's own commentary is cautious well beyond the trade dispute: Rémy Cointreau describes the Chinese market as "very challenging" and is resetting its commercial organisation there, signs that management is planning for a slow grind rather than a snap-back [29]. If Chinese cognac demand settles a rung lower, Martell's mid-cycle earning power is permanently smaller, regardless of how good the barrels are.

The evidence to date leans toward a cyclical read on cognac with a resolved trade overlay: the duty-free channel is back, the tariff is settled on a five-year framework at modest cost, Martell's Chinese New Year sell-out rebounded, and the underlying franchise is one of the best-protected in the industry. The strongest fact against that read is that China's reported sales were still −7% in the most recent quarter and the pure-play peer sees no near-term inflection [30]. What would decide it is Chinese cognac depletions turning positive on a clean comparison — not the duty-free restocking bounce, but sustained sell-out — over the next few quarters. Until then, the largest single driver of the fall is best described as a deep cyclical trough in a structurally sound category, with a real but unquantified risk that the trough is partly a new floor.

---

India: the region still growing

While China fell -21% in FY25 and cognac carried the group down, one large market kept compounding. India — Pernod Ricard's second-largest market by net sales [1] — grew organically every year through the downturn, from +26% in FY22 to +6% in FY25, and accelerated to +11% in the third quarter of FY26 [2]. It is a genuine structural offset on the sales line, powered by demographics no cycle removes. The qualification that matters: India is lower-margin than the cognac profit it is being asked to replace, and it carries state-excise and legal volatility of its own.

One region grew while the profit center collapsed

The clearest way to see India's role is against China, the market whose decline sits at the center of this dislocation (Cognac and China). The two moved in opposite directions through the entire drawdown.

Sources: FY2022 Sales & Results [3]; FY2025 Sales & Results [4]; Q3/9M FY2026 [5]; China FY24 per Cognac and China.

In FY25, India delivered +6% on "strong underlying consumer demand and premiumisation trends" in the same year China printed -21% [6]. The gap widened in FY26: through nine months India was +6% (with the third quarter at +11%) against China at -24% year-to-date [7]. India was already the standout of the recovery years — +26% in FY22, when management flagged it as the strongest of the must-win markets [8] — and it kept growing when the rest of the group turned negative.

A structural tailwind, not a cyclical rebound

What separates India from a normal cyclical recovery is the demographic base underneath it. Management quantifies it plainly: roughly 25 million people join the legal-drinking-age population every year, "for the foreseeable future," in what is already the world's largest whisky market [9]. That inflow, combined with a growing middle and affluent class, is the engine that carried India to the group's number-two position by net sales [10].

Sources: FY2024 Annual Report / URD, CEO interview [11] and must-win markets [12]; FY2024 earnings call [13].

The company is putting capital behind that read. In 2024 it announced investment plans of up to €200 million in India, including one of the country's biggest malt distilleries, under a Memorandum of Understanding with the Government of Maharashtra [14]. The imported portfolio travels well into this base: with over 500,000 nine-litre cases sold in FY24, India became Jameson's second-largest market globally [15]. This is the demand profile the bear case on Western moderation and GLP-1 (Demand Durability) does not touch — a young, urbanising, first-generation premium-spirits consumer, not a mature market defending its penetration.

Premiumisation, made visible by a disposal

India's growth is not just volume; management is deliberately trading up the mix, and it took a structural step to prove it. In late 2025 the group disposed of its Imperial Blue business — a large, mass-market Indian whisky brand — alongside its Wines operations [16]. The effect on the underlying growth rate is the cleanest evidence of the premiumisation: in the first half of FY26, India was +4% as reported but +8% excluding Imperial Blue [17]. Shedding the value-end brand lifts both the growth rate and the margin of what remains.

Sources: FY2024 Sales & Results [18]; FY2025 Sales & Results [19]; H1 FY2026 Sales & Results [20].

The engine driving the mix is the local Seagram's whisky portfolio — Royal Stag and Blender's Pride trading up, with the mass-market Imperial Blue divested — layered under the imported brands. The strategic framing in the FY24 report is explicit: "quality over quantity," positioning India as a hub for premium and luxury rather than volume [21]. For a group whose FY25 profit fell on cognac and China, a growing high-single-digit market that is actively improving its own margin is worth more than its share of sales suggests.

What the offset does not do

India cushions the growth line. Whether it backfills the profit is a different question, and the honest answer is: not fully, and not soon.

The arithmetic gap is structural. Chapter Cognac and China established that Asia/Rest-of-World generated €1,360m of recurring profit — roughly 46% of the group total — with cognac and China the highest-margin engine inside it. Indian whisky, even premiumising, sells at price points well below Martell cognac; the mix trade-up is real but it is climbing from a lower base. India can plausibly replace China's growth contribution long before it replaces China's profit contribution. The company does not disclose India's net sales or margin separately, so this cannot be pinned precisely — but the direction is not in doubt.

India also brings its own volatility, on two fronts:

• State excise policy. Alcohol is regulated state by state, and the rules move. Maharashtra excise changes were called out as a specific FY26 headwind, skewed to the first quarter [22] — the same state that signed the distillery MoU. State reopenings (such as Andhra Pradesh) cut the other way. The net effect is a growth line that is genuinely strong underneath but choppy quarter to quarter.
• A legal overhang. Pernod Ricard India is the subject of an Enforcement Directorate charge sheet, filed in a Delhi court in February 2023, alleging the local unit may have benefited from irregularities under the Delhi excise policy, in breach of India's anti-money-laundering law; separate long-running customs and tax disputes are also outstanding [23]. None of this is quantified as material to the group, and the company says it will contest the allegations, but it is a governance tail that a China-and-cognac-focused reading of the dislocation would otherwise miss.

The read: India is the most durable growth asset in the portfolio and the strongest single piece of evidence that the group's demand base is not uniformly impaired — its demographics are the antidote to the Western-moderation bear case. It is not, on its own, a full profit offset to a structurally lower China, and it adds regulatory and legal noise. It changes the odds on the permanent-impairment question (Demand Durability) more than it changes the near-term profit bridge. What would sharpen the read: separate India net-sales and margin disclosure, and evidence that the ex-Imperial-Blue growth rate holds once the disposal laps.

---

Ownership and Delivery

Pernod Ricard is controlled by the founding Ricard family: a concert party holding 15.1% of the capital but 21.9% of the votes, its roughly €2.4bn stake more than 400 times the CEO's annual pay and slightly larger than it was three years ago. On the promotional-CEO screen, that is the opposite profile — owner-operators, not option-holders managing to the next quarter. The counterweight is a delivery record that over-promised at the 2023 peak: the growth algorithm and the FY2024 buyback were both walked back.

A founding family in control

Alexandre Ricard — grandson of founder Paul Ricard — has held the combined role of Chairman and CEO since February 2015, when the board merged the two positions and, at the same meeting, capped his powers by requiring prior board authorisation for acquisitions or divestments above €100 million and loans above €200 million [1]. The control is exercised through a family concert party — Société Paul Ricard and the wider Ricard family holdings — that at 30 June 2025 held 15.13% of the share capital but 21.93% of the voting rights [2]. The wedge between the two is a double-voting right that attaches to registered shares held two years or more: 50,666,883 of the 252,269,195 shares outstanding — about a fifth — carry two votes each [3].

A second aligned bloc sits alongside the family. Groupe Bruxelles Lambert — the Frère-Desmarais investment holding — owns 6.82% of the capital and 11.36% of the votes, and its stake has not moved in three years [4]. Together the two long-term holders command roughly a third of the votes on a fifth of the capital.

Source: FY2025 Universal Registration Document, breakdown of share capital and voting rights [5]; concert-party aggregate [6]. "Free float and institutions" is the residual, including employees (1.35% capital) and named funds (MFS, BlackRock, Wellington and others).

The board itself is more independent than the control structure implies. At 30 June 2025 it counted 58.3% independent directors, 58.3% women and 42.9% non-French members, met ten times in the year, and is chaired for independent purposes by a Lead Independent Director, Patricia Barbizet [7]. The family and its representatives — César Giron, Patricia Ricard Giron, Veronica Vargas — sit as non-independent directors, and the shareholders' agreement between the family holding and the Gonzalez-Gallarza heirs is disclosed to the market regulator [8].

The alignment test

For Ruchir the governance question that matters is narrow: is management buying alongside, or is this a promotional executive paid to talk the stock without owning it. The arithmetic is decisive. The Ricard concert party's 38.2 million shares are worth about €2.44bn at €63.88, and Alexandre Ricard holds a further 215,609 shares in his own name — roughly €13.8m, itself more than twice his annual pay [9]. His FY2025 total compensation was €5.54m [10]. The family's wealth is tied to the share price by a factor of more than four hundred to one against his pay.

Source: stake valued at 38,163,571 concert shares × €63.88 close (3 July 2026); CEO compensation from the FY2025 URD compensation report [11].

The pay itself is structured the way an aligned owner would want. Fixed salary is 27% of the package, annual variable 29% and long-term equity 44%, with over 70% of the total contingent on performance [12]. The long-term grant vests over three years against profit from recurring operations (50% of the award), relative total shareholder return versus a peer panel (30%) and sustainability metrics (20%) — a multi-year, partly relative scorecard rather than a next-quarter earnings target [13]. The alignment shows up in the payout: the 2021 long-term plan's external TSR condition delivered a nil result, its annualised shareholder return over the vesting period being zero, so the plan paid well below the ~70-85% vesting of its predecessors [14]. His annual bonus moved the same way, from 151% of salary in FY2023 to 99% in FY2024 as results turned [15]. On the evidence, the promotional-CEO exclusion does not fit this company; the risk here runs the other way, toward entrenchment, which the closing section takes up.

Insiders held, and added, through the fall

Beyond structure, the more telling fact is direction. Playbook logic says insiders selling into a collapse points to informed selling; insiders adding points the other way. Through the drawdown, the people closest to the business did not sell.

Source: FY2025 Universal Registration Document, three-year breakdown of share capital and voting rights [16].

The family holding company edged up each year, directors and management added about 34,000 shares net, and Groupe Bruxelles Lambert did not sell a single share [17]. Over the same window BlackRock cut its position and fell below the 5% threshold in November 2024 [18]. The additions are small in absolute terms and part-mechanical — dividend-linked and routine — so they are a directional signal, not conviction buying at scale. But they are the opposite of an insider exit.

The delivery record

Where the file is less clean is promise against outcome. Management set its ambitions at the top of the cycle and has since retreated from them, twice in ways a careful reader should log.

Sources: medium-term framework reiterated at +4% to +7% [19], lowered to +3% to +6% [20]; buyback guidance [21] and execution [22].

At the FY2023 results in June 2023 the company raised its dividend 14% to €4.70 and announced a €500m-to-€800m buyback for FY2024, on the back of what it called a "very strong" year [23]. It executed €334m of that buyback in FY2024 and just €11m in FY2025 with the shares near their lows [24]. As late as August 2024 it was still reiterating a medium-term algorithm of "+4% to +7% aiming for the upper end" [25]; by February 2025 that had been cut to +3% to +6% [26]. The pattern of that period — large brand acquisitions (Sovereign Brands, Código, Skrewball) and near-€750m of buybacks funded partly by rising debt at what proved to be peak valuations [27] — is capital allocated pro-cyclically, the mirror image of the buybacks that never came at €64.

Two readings sit against each other here. One is that management misjudged the cycle and its own guidance was too confident at the peak — a mark against its calibration. The other is that lowering an algorithm during a genuine demand shock, and prioritising the dividend and the credit rating over buybacks when cash tightened (Cash and the Dividend), is realism rather than promotion — and the family-owner incentive structure removes the reason a hired manager might have kept talking up a number it could no longer hit. Both are true. The delivery record is a reason to discount management's forward numbers, not a reason to doubt that the owners are underwriting the same outcome as an outside buyer.

Control's double edge

The same family control that makes the alignment strong also caps what a minority holder can change. With roughly a third of the votes between the Ricard concert and Groupe Bruxelles Lambert, and a combined Chairman-CEO, there is no realistic path for an activist to force a break-up, a leadership change, or a faster balance-sheet reset — the disclosed limits on the CEO's powers are internal board controls, not minority protections [28]. For an investor whose instruments run eighteen months, that removes one class of catalyst: the report should not lean on a governance event to close the price-to-value gap.

Against that, a patient owner willing to hold brand investment and the dividend through a downturn, rather than cut both to defend a quarter, is closer to a feature than a bug on an eight-to-twenty-year clock — provided the patience does not become inertia in the face of the demand questions the rest of the report raises. The people with the most to lose are behaving as though the damage is temporary: they have added shares, held the payout, and kept investing behind the portfolio. That is a modest confirming signal on the report's central question, not a substitute for the demand and cash-flow evidence that has to decide it.

---

Valuation and Scenarios

At €63.88 Pernod Ricard trades at roughly 8x EV/EBITDA and 9.9x reported earnings — the deepest discount in the listed spirits group, on roughly double the dividend yield of any peer. That price sits close to what a permanently lower earning-power outcome is worth and well below what even a partial cyclical recovery implies. The gap the dislocation offers is real only if the demand problem is cyclical rather than structural; this chapter frames both outcomes and what would decide between them.

Where the price sits

Three of the prior chapters established the pieces of the valuation in isolation: the multiple compression that turned a 57% enterprise-value fall into a 70% equity fall (Damage Arithmetic), the sub-10% cash and dividend yields (Cash and the Dividend), and the reversed premiumisation behind the earnings decline (Demand Durability). Placed against the peer group, the multiple is unambiguous: Pernod Ricard is the cheapest large spirits name on every lens, and the cheapness is both absolute — against its own ~16-18x EV/EBITDA at the 2021–22 peak — and relative to peers trading today at 11–13x.

Sources: Pernod Ricard reported diluted EPS €6.45 and DPS €4.70 on the €63.88 close [1] [2]; EV/EBITDA per Damage Arithmetic; peer multiples and yields from market data (Diageo, Brown-Forman, Rémy Cointreau, Campari), as of February–July 2026. Pernod P/E is trailing (fwd ~11.1x on ~€5.77 consensus); Diageo P/E is forward.

The dividend yield tells the same story from a different angle. Pernod Ricard's 7.4% is roughly twice Diageo's 3.9%, Brown-Forman's 3.5% or Rémy Cointreau's 3.7%, and four times Campari's 1.8% [1]. A yield gap that wide is not a market oversight; it is the market pricing a materially higher chance that this dividend, unlike the others, is cut. The FY2025 payout was covered 0.94x by reported free cash flow (€1,201m paid against €1,133m generated) and only 1.12x on the recurring measure [3] — the tension the yield is compensating for.

Two scenarios

The valuation resolves into a single question already named as the through-line: is the earnings decline a cyclical trough that repairs, or a step down to permanently lower earning power? The two ends of that range produce very different values, and the current price is far closer to one of them.

The anchor is recurring net profit per share, which fell from €9.11 at the FY2023 peak to €7.26 in FY2025, with consensus near €5.77 for FY2026 [1]. The table below applies a normalized earnings level and a multiple to each scenario. The multiples are deliberately conservative — the upside cases re-rate only partway toward where peers trade today, not back to Pernod's own peak.

Source: derived from reported financials — recurring EPS path €9.11 (FY23) to €7.26 (FY25) [1] — and consensus; multiples are the author's assumptions, stated for transparency, not a forecast.

Source: scenario table above; current price €63.88 as of 3 July 2026. Derived from reported financials and consensus.

The reconciliation is the point. At €63.88 the market is paying almost exactly what the structural-base scenario is worth — earning power settling near the depressed FY2026 level with only modest growth. That is consistent with the reverse-DCF in Damage Arithmetic, which found the price implies roughly zero-to-two-percent perpetual free-cash-flow growth against a ~6.7% historical rate. Both lenses say the same thing: today's price underwrites near-permanent stagnation. It does not require a recovery to work as a value — it requires only that the business not decline. The upside, by contrast, is entirely a function of the demand read being cyclical: a partial repair toward the consensus median target of €88.5 is roughly +39%, and a fuller recovery is +80%, with a ~7% dividend collected each year in the interim if the payout holds.

The evidence on which scenario is unfolding is genuinely mixed, which is why the price is where it is. Q3 FY2026 showed group volumes back to +4% and organic sales at +0.1%, the first stabilisation after two years of decline [4]. That cuts toward cyclical. But volumes recovered while price/mix stayed negative — the downtrading signature (Demand Durability) — so the profit that matters has not yet turned, and management's own FY2027–2029 algorithm of +3% to +6% organic growth assumes a recovery it has not yet delivered [5].

Bull and bear on shared facts

The two cases are best set against the same numbers rather than competing narratives. Each row below is a fact from the filings; the disagreement is entirely about what it means.

Sources: EV/EBITDA and reverse-DCF per Damage Arithmetic; dividend cover [3]; Q3 volumes and organic sales [4]; family voting control per Ownership and Delivery.

No single row decides the case, and the honest reading is that they will not be decided by argument — only by the operating data over the next several quarters. The strongest fact for the bull is that the multiple has already compressed to a level that survives a no-growth outcome, so the downside is bounded unless earning power actually falls further or the dividend is cut. The strongest fact for the bear is that price/mix — the mechanism that carried premium-spirits earnings for a decade — is still going the wrong way, and a valuation that looks cheap on trailing earnings looks ordinary on a permanently lower base.

What to watch

The recovery mechanisms that matter for a value investor's ~18–24 month clock are the near-term ones: the end of US destocking and the resumption of duty-free cognac in China both plausibly land inside that window (Cognac and China). The structural-demand question — whether Western moderation is a cycle or a secular decline — will not be settled inside it, and that limitation should be stated rather than hidden. The list below is falsifiable: each item names the line to check, the filing it appears in, and the threshold that would move the read.

Sources: quarterly organic splits, China and US organic, and volumes from the Q3 FY2026 sales release [4]; FY2027–2029 organic algorithm [5]; net debt/EBITDA 3.3x and FCF €1.1bn [1]; proposed dividend of €4.70 per share [6]; consensus revisions from analyst estimates.

The dividend decision is the most compact tell. Held flat at €4.70 while free cash flow recovers, it signals a board that reads the trough as temporary; cut toward the roughly €3.63 that the stated ~50%-of-recurring-net-profit policy implies, and it confirms the coverage strain the yield already prices (Cash and the Dividend). Either way, the single most informative number to track is not the dividend or the multiple but price/mix: a return to positive price/mix is the evidence that would move this from the structural-base value where it trades toward the cyclical-recovery value it could reach.